NCT04820023 2025-06-06Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI TreatmentBridge Biotherapeutics, Inc.Phase 1/2 Terminated45 enrolled 19 charts
NCT01976741 2021-05-06Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)BayerPhase 1 Completed168 enrolled 59 charts